Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
12/1999
12/16/1999WO1999064035A1 β2-ADRENERGIC RECEPTOR AGONISTS
12/16/1999WO1999064034A1 β2-ADRENERGIC RECEPTOR AGONISTS
12/16/1999WO1999064031A1 β2-ADRENERGIC RECEPTOR AGONISTS
12/16/1999WO1999064021A1 hCEPR RECEPTOR
12/16/1999WO1999064017A1 Method and system for production and collection of lavage induced stool (lis) for chemical and biologic tests of cells
12/16/1999WO1999064014A1 Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma
12/16/1999WO1999064001A2 Methods and compositions for increasing penetration of hiv protease inhibitors
12/16/1999WO1999064000A1 Novel therapeutic agents that modulate neurokinin receptors
12/16/1999WO1999063999A1 H1-histamine receptor antagonists
12/16/1999WO1999063996A1 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5ht2 receptors
12/16/1999WO1999063993A1 Multivalent agonists, partial agonists, inverse agonists and antagonists of the d1 receptors
12/16/1999WO1999063984A1 Novel sodium channel drugs and uses
12/16/1999WO1999063983A1 MULTIBINDING AGENTS THAT MODULATE PPARη AND RXR RECEPTORS
12/16/1999WO1999063982A1 Wound treatment through inhibition of adenosine diphosphate ribosyl transferase
12/16/1999WO1999063981A2 Use of alkylating compounds for inhibiting proliferation of arterial smooth muscle cells
12/16/1999WO1999063980A1 Treatment of anti-estrogen resistant breast cancer using rxr modulators
12/16/1999WO1999063976A2 Liver-selective glucocorticoid antagonist for treating diabetes
12/16/1999WO1999063975A2 A method for stimulating the immune system
12/16/1999WO1999063974A2 Selective estrogen receptor modulator in combination with denydroepiandrosterone (dhea) or analogues
12/16/1999WO1999063944A2 Novel therapeutic agents that modulate estrogen receptors
12/16/1999WO1999063943A2 Nutritional methyl supplements change epigenetics, dna methylation, phenotype, and appearance of mammalian offspring
12/16/1999WO1999063938A2 Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs
12/16/1999WO1999063936A2 Novel therapeutic agents that modulate endothelin receptors
12/16/1999WO1999063935A2 Rapid opioid detoxification therapy and anti-readdiction therapy
12/16/1999WO1999063933A2 Multivalent agonists, partial agonists and antagonists of the gaba receptors
12/16/1999WO1999063932A2 Multibinding agents that modulate the 5-ht transporter
12/16/1999WO1999063930A2 Novel angiotensin receptor modulators and their uses
12/16/1999WO1999049877A3 Methods for reducing cholesterol using bacillus coagulans spores, systems and compositions
12/16/1999WO1999048461A3 Substituted aromatic compounds for treatment of antibiotic resistant infections
12/16/1999WO1999043807A3 Human channel-related molecules
12/16/1999WO1999041375A3 Human receptor proteins
12/16/1999WO1999041373A3 Human transport-associated molecules
12/16/1999WO1999041368A3 Optimization of immunomodulatory properties of genetic vaccines
12/16/1999WO1998024902A8 Adaptor protein frs2 and related products and methods
12/16/1999CA2768882A1 Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
12/16/1999CA2768841A1 Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
12/16/1999CA2768828A1 Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
12/16/1999CA2768773A1 Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
12/16/1999CA2768682A1 Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
12/16/1999CA2334895A1 Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
12/16/1999CA2334872A1 Use of exendin-4 to treat impaired glucose tolerance
12/16/1999CA2334850A1 Novel methods and interferon deficient substrates for the propagation of viruses
12/16/1999CA2334545A1 Treatment of anti-estrogen resistant breast cancer using rxr modulators
12/16/1999CA2334338A1 Directed combinatorial compound library and high throughput assays for screening same
12/16/1999CA2334116A1 Treatment of diabetes
12/16/1999CA2332314A1 Use of alkylating compounds for inhibiting proliferation of arterial smooth muscle cells
12/16/1999CA2331372A1 Tankyrase, a trfi binding protein
12/16/1999CA2329688A1 Cell cycle regulation proteins
12/16/1999CA2329685A1 Proteins regulating gene expression
12/16/1999CA2329160A1 Wound treatment through inhibition of adenosine diphosphate ribosyl transferase
12/16/1999CA2321273A1 Novel analgesic agents
12/16/1999CA2321170A1 Multivalent agonists, partial agonists, inverse agonists and antagonists of the d1 receptors
12/16/1999CA2321152A1 Novel therapeutic agents that modulate endothelin receptors
12/16/1999CA2321120A1 .beta.3-adrenergic receptor agonists
12/16/1999CA2320926A1 Novel leukotriene receptor antagonists and their uses
12/16/1999CA2319756A1 Novel therapeutic agents that modulate alpha-1a adrenergic receptors
12/16/1999CA2319751A1 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5ht2 receptors
12/16/1999CA2319651A1 H1-histamine receptor antagonists
12/16/1999CA2319643A1 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5ht4 receptors
12/16/1999CA2319497A1 Novel therapeutic agents that modulate estrogen receptors
12/16/1999CA2319496A1 Multivalent agonists, partial agonists and antagonists of the gaba receptors
12/16/1999CA2319175A1 Multibinding agents that modulate nmda receptors
12/16/1999CA2319159A1 Novel therapeutic agents that modulate neurokinin receptors
12/16/1999CA2319153A1 Novel sodium channel drugs and uses
12/16/1999CA2319142A1 Novel therapeutic agents for membrane transporters
12/16/1999CA2319068A1 Novel angiotensin receptor modulators and their uses
12/16/1999CA2318894A1 .beta.2-adrenergic receptor agonists
12/16/1999CA2318806A1 Multibinding agents that modulate the 5-ht transporter
12/16/1999CA2318745A1 Novel potassium channel drugs and their uses
12/16/1999CA2318286A1 Multibinding agents that modulate ppar.gamma. and rxr receptors
12/16/1999CA2318055A1 .beta.2-adrenergic receptor agonists
12/16/1999CA2316994A1 Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs
12/16/1999CA2300082A1 Fixation inhibitors for helicobacter pylori
12/16/1999CA2293694A1 New carboxypeptidase inhibitor
12/15/1999EP0963440A1 Improved methods for transducing cells
12/15/1999EP0963431A1 NOVEL FabH
12/15/1999EP0963203A2 Mammalian tolloid-like gene and protein
12/15/1999EP0963202A1 Formulations and methods for providing prolonged local anesthesia
12/15/1999EP0963200A2 Methods and compositions for inhibition of angiogenesis
12/15/1999EP0963197A1 Guanylhydrazones useful for treating diseases associated with t cell activation
12/15/1999EP0658110B1 Use of norastemizole for the treatment of allergic rhinitis
12/15/1999EP0646008B1 Minimizing progestin associated breakthrough bleeding
12/15/1999EP0414730B1 Chemical Compounds and pharmaceutical compositions capable of releasing a drug
12/15/1999CN1238783A Method and novel compounds for use therein
12/15/1999CN1238771A 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agonists
12/15/1999CN1238700A Improvents in or relating to diagnostic/therapeutic agents
12/15/1999CN1238695A Topical composition for preventing or treating bacterial skin infections
12/15/1999CN1238693A Pharmaceutical composition comprising compound having anti-Xa activity and platelet aggregation antagonist compound
12/15/1999CN1238690A Improved pharmaceutical compositions
12/15/1999CN1238689A Vitronectin receptor antagonists
12/14/1999US6001992 Oligonucleotides which promote apoptosis; anticarcinogenic agents, viricides, and treatment of autoimmune disorders
12/14/1999US6001972 Splicing variant of the epstein-barr virus-induced G-protein coupled receptor
12/14/1999US6001868 Administering to an individual an effective amount of an indole-3-carbinol compound or a derivative to treat tumor cell growth
12/14/1999US6001823 Novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones
12/14/1999US6001623 Polynucleotide sequence coding a human enzymatic polypeptide; for developing treatments and diagnostic assays for disease
12/14/1999US6001603 Polynucleotide sequence coding for a staphylococcus enzmatic protein; for diagnosis, treatment and prevention of bacterial infections; bactericides
12/14/1999US6001602 DNA encoding Chlamydia trachomatis isoleucyl tRNA synthetase polypeptides
12/14/1999US6001581 Cation-based bioassay using human metabotropic glutamate receptors
12/14/1999US6001357 Method of enhancing wound healing with anti-IL-5 antibody
12/14/1999US6001347 Organic acid compound of given structure having an aromatic amide group, a methoxy group in the ortho position on the aromatic ring, and a lipophilic chain terminated with a carboxylic acid is useful as a nontoxic carrier
1 ... 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 ... 1151